Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: Triester derivatives incorporating amino acid residues

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 7, 2004, Pages 1697-1712

  Tardy, Christelle ^a   Facompré, Michaël ^a   Laine, William ^a   Baldeyrou, Brigitte ^a   García Gravalos, Dolores ^b   Francesch, Andrés ^b   Mateo, Cristina ^b   Pastor, Alfredo ^b   Jiménez, José A ^b   Manzanares, Ignacio ^b   Cuevas, Carmen ^b   Bailly, Christian ^a  

^a INSERM   (France)

^b PHARMAMAR S A   (Spain)

Author keywords

Anticancer drugs; Camptothecin; CPT; Cytotoxicity; DNA interaction; LAM D; Lamellarin; Lamellarin D; Topoisomerase I

Indexed keywords

3,11 DIISOPROPOXY 14 (4 ISOPROPOXY 3 METHOXYPHENYL) 2,12 DIMETHOXY 6H [1]BENZOPYRANO[4',3':4,5]PYRROLO[2,1 A]ISOQUINOLIN 6 ONE; 5,6 DIHYDRO 3,11 DIISOPROPOXY 14 (4 ISOPROPOXY 3 METHOXYPHENYL) 2,12 DIMETHOXY 6H [1]BENZOPYRANO[4',3':4,5]PYRROLO[2,1 A]ISOQUINOLIN 6 ONE; ALKALOID; AMINO ACID; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ESTER DERIVATIVE; LAMMELLARIN D; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CHROMATOPHORE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA DETERMINATION; DNA PROTEIN COMPLEX; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MALE; MELTING POINT; PROTEIN DNA BINDING; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ALKALOIDS; AMINO ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; DNA; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; ISOQUINOLINES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12144288129     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.01.020     Document Type: Article

References (18)

1. Rinehart K.L. Med. Res. Rev. 20:2000;1.
2. da Rocha A.B., Lopes R.M., Schwartsmann G. Curr. Opin. Pharmacol. 1:2001;364.
3. Vera M.D., Joullié M.M. Med. Res. Rev. 22:2002;102.
4. Clamp A., Jayson G. Anticancer Drugs. 13:2002;673.
5. Mayer A.M., Gustafson K.R. Int. J. Cancer. 105:2003;291.
6. Erba E., Bergamaschi D., Bassano L., Damia G., Ronzoni S., Faircloth G.T., D'Incalci M. Eur. J. Cancer. 37:2001;97.
7. Aune G.J., Furuta T., Pommier Y. Anticancer Drugs. 13:2002;545.
8. Andersen R.J., Faulkner D.J., He C.-H., Van Duyne G.D., Clardy J. J. Am. Chem. Soc. 107:1985;5492.
9. Davis R.A., Carroll A.R., Pierens G.K., Quinn R.J. J. Nat. Prod. 62:1999;419.
10. Quesada A.R., García Gravalos M.D., Fernández Puentes J.L. Br. J. Cancer. 74:1996;677.
11. Facompré M., Tardy C., Bal-Mayeu C., Colson P., Pérez C., Manzanares I., Cuevas C., Bailly C. Cancer Res. 63:2003;7392.
12. Banwell M.G., Hockless D. Chem. Comm. 23:1997;2259.
13. Bailly C. Methods Enzymol. 340:2001;610.
14. Jaxel C., Capranico G., Kerrigan D., Kohn K.W., Pommier Y. J. Biol. Chem. 266:1991;20418.
15. Pommier Y., Kohlhagen G., Kohn K.W., Leteurtre F., Wani M.C., Wall M.E. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8861.
16. Rossi F., Labourier E., Forné T., Divita G., Derancourt J., Riou J.F., Antoine E., Cathala G., Brunel C., Tazi J. Nature. 381:1996;80.
17. Faircloth G.T., Stewart D., Clement J.J. J. Tissue Cult. Methods. 11:1988;201.
18. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. J. Natl. Cancer Inst. 82:1990;1107.